tetano
Editor, Senior Moderator
Respir Investig
. 2022 Apr 25;S2212-5345(22)00045-4.
doi: 10.1016/j.resinv.2022.04.001. Online ahead of print.
Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution
Takashi Ichiyama[SUP] 1 [/SUP], Masamichi Komatsu[SUP] 2 [/SUP], Yosuke Wada[SUP] 2 [/SUP], Masayuki Hanaoka[SUP] 2 [/SUP]
Affiliations
Abstract
Many drugs have been marketed for treating coronavirus disease 2019 (COVID-19) infection, the disease that has caused a worldwide pandemic. However, in reported clinical trials, almost 30% of patients with COVID-19 did not show any health improvement. The 28-day survival rate was 69.5% when patients who required highflow oxygen therapy (HFNC), ventilation, and extracorporeal membrane oxygenation (ECMO) management were treated with remdesivir. The mortality rate of patients receiving 6 mg dexamethasone was 27%, and that of patients treated with tocilizumab and steroids was 31%. These results are unsatisfactory, and treatment for patients with severe respiratory failure has not yet been established. In our institution, we used remdesivir, methylprednisolone (mPSL) pulse therapy, and tocilizumab in 20 patients with COVID-19 whose PaO2/FIO2 (P/F) ratio was <200, and obtained good results for this combination therapy without any adverse events. In this study, we report the possible efficacy and safety of this treatment.
Keywords: Coronavirus disease 2019; Methylprednisolone pulse; Remdisivir; Tocilizumab.
. 2022 Apr 25;S2212-5345(22)00045-4.
doi: 10.1016/j.resinv.2022.04.001. Online ahead of print.
Report of a combination of remdesivir, intravenous methylprednisolone pulse, and tocilizumab for severe coronavirus disease: 20-case series at a single institution
Takashi Ichiyama[SUP] 1 [/SUP], Masamichi Komatsu[SUP] 2 [/SUP], Yosuke Wada[SUP] 2 [/SUP], Masayuki Hanaoka[SUP] 2 [/SUP]
Affiliations
- PMID: 35501265
- DOI: 10.1016/j.resinv.2022.04.001
Abstract
Many drugs have been marketed for treating coronavirus disease 2019 (COVID-19) infection, the disease that has caused a worldwide pandemic. However, in reported clinical trials, almost 30% of patients with COVID-19 did not show any health improvement. The 28-day survival rate was 69.5% when patients who required highflow oxygen therapy (HFNC), ventilation, and extracorporeal membrane oxygenation (ECMO) management were treated with remdesivir. The mortality rate of patients receiving 6 mg dexamethasone was 27%, and that of patients treated with tocilizumab and steroids was 31%. These results are unsatisfactory, and treatment for patients with severe respiratory failure has not yet been established. In our institution, we used remdesivir, methylprednisolone (mPSL) pulse therapy, and tocilizumab in 20 patients with COVID-19 whose PaO2/FIO2 (P/F) ratio was <200, and obtained good results for this combination therapy without any adverse events. In this study, we report the possible efficacy and safety of this treatment.
Keywords: Coronavirus disease 2019; Methylprednisolone pulse; Remdisivir; Tocilizumab.